NASDAQ:NURO NeuroMetrix (NURO) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free NURO Stock Alerts $4.44 0.00 (0.00%) (As of 11:48 AM ET) Add Compare Share Share Today's Range$4.34▼$4.4450-Day Range$2.94▼$4.5752-Week Range$2.70▼$11.60Volume7,969 shsAverage Volume43,427 shsMarket Capitalization$8.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get NeuroMetrix alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About NeuroMetrix Stock (NASDAQ:NURO)NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Read More NURO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NURO Stock News HeadlinesApril 24, 2024 | finance.yahoo.comNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearApril 20, 2024 | investing.comNeuroMetrix appoints new board director, ends ATM facilityApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 19, 2024 | markets.businessinsider.comNeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement StepsApril 19, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueApril 19, 2024 | globenewswire.comNeuroMetrix Announces Steps Taken to Enhance Shareholder ValueApril 18, 2024 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.comMarch 14, 2024 | globenewswire.comNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaMarch 13, 2024 | globenewswire.comNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaMarch 8, 2024 | finanznachrichten.deRS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.March 8, 2024 | finance.yahoo.comRS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.February 25, 2024 | au.lifestyle.yahoo.comGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesFebruary 24, 2024 | finance.yahoo.comNeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)February 23, 2024 | finance.yahoo.comNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | finance.yahoo.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | globenewswire.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 15, 2024 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 15, 2024 | globenewswire.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueFebruary 13, 2024 | markets.businessinsider.comNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsFebruary 13, 2024 | finance.yahoo.comNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueJanuary 8, 2024 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024December 12, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell in Post-Acute COVID-19 Syndrome (Long COVID)December 12, 2023 | finance.yahoo.comNeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)See More Headlines Receive NURO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/24/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NURO CUSIPN/A CIK1289850 Webwww.neurometrix.com Phone(781) 890-9989Fax302-636-5454Employees26Year Founded1996Profitability EPS (Most Recent Fiscal Year)($6.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,530,000.00 Net Margins-110.64% Pretax Margin-110.64% Return on Equity-31.31% Return on Assets-29.32% Debt Debt-to-Equity RatioN/A Current Ratio16.80 Quick Ratio15.55 Sales & Book Value Annual Sales$5.90 million Price / Sales1.49 Cash FlowN/A Price / Cash FlowN/A Book Value$13.18 per share Price / Book0.34Miscellaneous Outstanding Shares1,990,000Free Float1,900,000Market Cap$8.82 million OptionableNot Optionable Beta2.26 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Shai N. Gozani M.D. (Age 59)Ph.D., Founder, Chairman, CEO, President & Secretary Comp: $437.82kMr. Thomas T. Higgins (Age 72)Senior VP, CFO & Treasurer Comp: $342.87kDr. Xuan Kong Ph.D.Chief Data ScientistMs. Susan M. Bell R.N.Senior Vice President of Population Health & Value Based CareKey CompetitorsIntelligent Bio SolutionsNASDAQ:INBSVapothermNYSE:VAPOVivos TherapeuticsNASDAQ:VVOSPlus TherapeuticsNASDAQ:PSTVAvingerNASDAQ:AVGRView All CompetitorsInstitutional OwnershipCerity Partners LLCBought 30,000 shares on 1/26/2024Ownership: 2.804%View All Institutional Transactions NURO Stock Analysis - Frequently Asked Questions How have NURO shares performed in 2024? NeuroMetrix's stock was trading at $3.60 at the start of the year. Since then, NURO shares have increased by 20.6% and is now trading at $4.34. View the best growth stocks for 2024 here. Are investors shorting NeuroMetrix? NeuroMetrix saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 11,300 shares, a drop of 51.3% from the March 15th total of 23,200 shares. Based on an average trading volume of 44,800 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the company's stock are sold short. View NeuroMetrix's Short Interest. When is NeuroMetrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our NURO earnings forecast. How were NeuroMetrix's earnings last quarter? NeuroMetrix, Inc. (NASDAQ:NURO) released its earnings results on Thursday, February, 22nd. The medical device company reported ($1.43) earnings per share for the quarter. The medical device company had revenue of $1.32 million for the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 31.31% and a negative net margin of 110.64%. When did NeuroMetrix's stock split? NeuroMetrix's stock reverse split before market open on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What is Shai N. Gozani's approval rating as NeuroMetrix's CEO? 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeuroMetrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Advanced Micro Devices (AMD) and Vaxart (VXRT). How do I buy shares of NeuroMetrix? Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NURO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
